Chronic inflammatory demyelinating polyneuropathy: Update on diagnosis, immunopathogenesis, and treatment
Semaglutide Clinical Data The STEP trial program represents the most comprehensive clinical evaluation of any GLP-1 receptor agonist for weight management: STEP 1: 14.9% mean body weight loss over 68 weeks (Wilding et al., NEJM , 2021) STEP 3: 16.0% with intensive behavioral therapy over 68 weeks STEP 5: Sustained 15.2% weight loss maintained at 104 weeks with continued treatment SELECT trial: Demonstrated 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in addition to weight loss, establishing cardiovascular benefit (Lincoff et al., NEJM , 2023) The SELECT trial result is particularly significant because it demonstrated that semaglutide provides cardiovascular protection independent of weight loss, a benefit that has not been established for tesofensine
Reduces fatigue and fatigue: Vitamin B6 helps reduce fatigue, giving you more energy and concentration
Feeding Instructions *Amounts are based on a standard 8 oz measuring cup
This does not mean NAD precursors reverse aging
This shift necessitates a move to branded medications like Wegovy, approved for weight loss with a BMI 30 or 27 with comorbidities
